Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Nuclear Medicine|March 3, 2025
Somatostatin Receptor-Directed Theranostics in EsthesioneuroblastomaYingjun Zhi, Sebastian E Serfling, Daniel Groener, et al.
Cancers|August 12, 2023
Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CTDaniel Groener, Jennifer Wichert, Magdalena Adams, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
Real-World Comparison of Cabazitaxel Versus <sup>177</sup>Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate CancerMike Wenzel, Florestan Koll, Benedikt Hoeh, et al.
Diagnostics (Basel, Switzerland)|June 24, 2022
Diagnostic Performance of <sup>99m</sup>Tc-Methoxy-Isobuty-Isonitrile (MIBI) for Risk Stratification of Hypofunctioning Thyroid Nodules: A European Multicenter StudySimone Agnes Schenke, Alfredo Campennì, Murat Tuncel, et al.
Journal of Clinical Medicine|May 14, 2022
Introducing a Pole Concept for Nodule Growth in the Thyroid Gland: Taller-than-Wide Shape, Frequency, Location and Risk of Malignancy of Thyroid Nodules in an Area with Iodine DeficiencyManuela Petersen, Simone A Schenke, Michael Zimny, et al.
Diagnostics (Basel, Switzerland)|October 16, 2024
Interobserver Agreement in Ultrasound Risk Stratification Systems for Thyroid Nodules on Static Images Versus Cine-Loop Video SequencesSimone Agnes Schenke, Manuela Petersen, Rainer Görges, et al.
EJNMMI Research|July 3, 2021
Hematologic safety of <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancerDaniel Groener, Cam Tu Nguyen, Justus Baumgarten, et al.
Scientific Reports|June 19, 2024
Miniaturized electromagnetic tracking enables efficient ultrasound-navigated needle insertionsAlexander Seitel, Daniel Groener, Matthias Eisenmann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Pageof 3